Patents by Inventor Michael Kavanaugh

Michael Kavanaugh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTIVATABLE POLYPEPTIDE COMPLEX
    Publication number: 20230183382
    Abstract: The present disclosure relates to activatable anti-EGFR, anti-CD3, heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 15, 2023
    Applicants: CytomX Therapeutics, Inc., Amgen, Inc.
    Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
  • ACTIVATABLE POLYPEPTIDE COMPLEX
    Publication number: 20230174995
    Abstract: The present disclosure relates to activatable heteromultimeric bispecific polypeptide complexes (HBPCs) and methods of making and using the same.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 8, 2023
    Applicants: CytomX Therapeutics, Inc., Amgen, Inc.
    Inventors: Leila M. BOUSTANY, Madan M. PAIDHUNGAT, Ellaine Anne Mariano FOX, Sayantan MITRA, W. Michael KAVANAUGH, Raffaella BRIANTE, Jennitte LeAnn STEVENS
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220023439
    Abstract: Provided herein are activatable antibodies that when activated specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 1, 2019
    Publication date: January 27, 2022
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan A. TERRETT, Annie Yang WEAVER, Matthias WILL
  • Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof
    Patent number: 11034759
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 15, 2021
    Assignees: Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210100913
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 21, 2020
    Publication date: April 8, 2021
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan TERRETT, Annie Yang WEAVER, Matthias WILL
  • SYSTEMS AND METHODS FOR QUANTITATIVE PHARMACOLOGICAL MODELING OF ACTIVATABLE ANTIBODY SPECIES IN MAMMALIAN SUBJECTS
    Publication number: 20210020264
    Abstract: The present invention provides methods and systems useful for modeling the pharmacology of an activated binding polypeptide or activatable antibody in a mammalian subject.
    Type: Application
    Filed: March 20, 2019
    Publication date: January 21, 2021
    Inventors: Mark Anthony Stroh, Jason Gary Sagert, Joshua F. Apgar, Bjorn L. Millard, Lin Lin, John M. Burke, W. Michael Kavanaugh
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20190263900
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: October 12, 2018
    Publication date: August 29, 2019
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190117789
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: August 30, 2018
    Publication date: April 25, 2019
    Inventors: LORI CARMAN, RACHEL HUMPHREY, W. MICHAEL KAVANAUGH, JONATHAN TERRETT, ANNIE YANG WEAVER, MATTHIAS WILL
  • Angiogenically Effective Unit Dose Of FGF And Method Of Administering
    Publication number: 20180221446
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: September 8, 2017
    Publication date: August 9, 2018
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • M-CSF Specific Monoclonal Antibody and Uses Thereof
    Publication number: 20180171009
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 21, 2018
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9926371
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: March 27, 2018
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • SLAMF1 ANTAGONISTS AND USES THEREOF
    Publication number: 20180016555
    Abstract: Methods of identifying and using SLAMF1 antagonists are provided.
    Type: Application
    Filed: October 21, 2015
    Publication date: January 18, 2018
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Luis Borges, Nathan Sallee, Charles Kaplan, Arthur Brace, W. Michael Kavanaugh, Brian Wong, David Bellovin, Thomas Brennan, Artur Karasyov
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20170152311
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: June 1, 2017
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses therof
    Patent number: 9522186
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 20, 2016
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING
    Publication number: 20160120943
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: September 28, 2015
    Publication date: May 5, 2016
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEROF
    Publication number: 20160015809
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: June 3, 2015
    Publication date: January 21, 2016
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins
    Patent number: 9169313
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: October 27, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, W. Michael Kavanaugh
  • Method of treating coronary artery disease by administering FGF-9
    Patent number: 9149507
    Abstract: The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-9 of SEQ ID NO:13, or an angiogenically active fragment or mutein thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: October 6, 2015
    Assignee: Novartis Vaccines and Dignostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMAINS
    Publication number: 20140274898
    Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
    Type: Application
    Filed: February 20, 2014
    Publication date: September 18, 2014
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
  • USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2
    Publication number: 20140227263
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Application
    Filed: November 14, 2013
    Publication date: August 14, 2014
    Applicant: FIVE PRIME PHARMACEUTICALS, INC.
    Inventors: Thomas Harding, W. Michael Kavanaugh